Search

everythinglearnresearchcommunity

for

Search:↓

The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.

Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.

Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.

The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.

Birt–Hogg–Dubé Syndrome requires genetic testing for accurate diagnosis due to its similarities with tuberous sclerosis.

Some children with localized scleroderma are rarely resistant to methotrexate, and no common profile for resistance was found.

Dimethyl-fumarate may cause temporary hair loss.

A certain medication improved severe itching in a boy with liver and bowel disease by reducing histamine levels, suggesting a new treatment target.

Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.

A Japanese man with rare skin conditions improved with hydroxychloroquine treatment.

A rare case of scleredema in a diabetic woman showed loss of sweat glands, causing heat strokes, with treatment only slightly improving symptoms.

Hyaluronic acid injections can improve mouth opening and quality of life in scleroderma patients.

Ayurvedic treatments can improve symptoms and quality of life for systemic sclerosis patients.

A high fat lard diet may protect against skin fibrosis and affect hair growth.

Early referral to a pediatric rheumatologist and thorough evaluation are crucial for treating complex overlap syndromes effectively.

Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.

Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.

A woman with systemic sclerosis developed a unique scarring hair loss combining features of systemic sclerosis and frontal fibrosing alopecia.

Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.

A woman with severe hair loss due to systemic sclerosis regrew her hair in 4 months using a combination of treatments.

Skin tumor cells in patients with tuberous sclerosis have higher levels of a protein called cathepsin B.

Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Platelet-rich Plasma Gel may help treat en coup de sabre scleroderma, improving symptoms and skin quality with minimal side effects.

Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.

The study concluded that patients with total hair loss and recurring hair loss had an earlier onset, longer-lasting condition, and a greater negative impact on their quality of life, with allergic conditions linked to more severe hair loss.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.